Charles Schwab Investment Management Inc Cardiff Oncology, Inc. Transaction History
Charles Schwab Investment Management Inc
- $429 Billion
- Q1 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 16,399 shares of CRDF stock, worth $36,405. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,399
Previous 16,399
-0.0%
Holding current value
$36,405
Previous $24,000
262.5%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding CRDF
# of Institutions
86Shares Held
8.48MCall Options Held
798KPut Options Held
39.2K-
Vanguard Group Inc Valley Forge, PA1.92MShares$4.27 Million0.0% of portfolio
-
Laurion Capital Management LP New York, NY929KShares$2.06 Million0.04% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny683KShares$1.52 Million0.0% of portfolio
-
Black Rock Inc. New York, NY677KShares$1.5 Million0.0% of portfolio
-
Mai Capital Management551KShares$1.22 Million0.03% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $96.2M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...